Publications by authors named "Matko Kalac"

Claim this Profile
E
Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age.
Neal D Shore, Ugo De Giorgi, Matko Kalac, Yiyun Tang, Ruslan Croitoru

Eur J Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer.
Neal D Shore, Murilo de Almeida Luz, Ugo De Giorgi, Martin Gleave, Geoffrey T Gotto, Matko Kalac

N Engl J Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial.
Karim Fizazi, Arun A Azad, Nobuaki Matsubara, Joan Carles, André P Fay, Matko Kalac

Lancet· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial.
Neeraj Agarwal, Arun A Azad, Joan Carles, André P Fay, Nobuaki Matsubara, Matko Kalac

Lancet· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current and upcoming treatment approaches to uncommon subtypes of PTCL (EATL, MEITL, SPTCL, and HSTCL).
Enrica Marchi, Jeffrey W Craig, Matko Kalac

Blood· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD19-Targeted Chimeric Antigen Receptor T-cell Therapy for Concomitant Diffuse Large B-cell Lymphoma and Multiple Myeloma.
Tyler D'Ovidio, Kathryn Ciccolini, Matko Kalac, Keren Osman, Amir Steinberg

Cureus· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Idiopathic CD4+ T-lymphocytopaenia with mutation complicated by progressive multifocal leucoencephalopathy and EBV+ polymorphic lymphoproliferative disorder.
Noa Rippel, Joshua Wong, Shafinaz Hussein, Matko Kalac

BMJ Case Rep· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world experience of combined treatment with azacitidine and romidepsin in patients with peripheral T-cell lymphoma.
Matko Kalac, Salvia Jain, Constantine S Tam, Zhengrui Xiao, Francesca Montanari

Blood Adv· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute cardiomyopathy following a single dose of doxorubicin in a patient with adult T-Cell leukemia/lymphoma.
Kyle Farina, Matko Kalac, Sara Kim

J Oncol Pharm Pract· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
-
-quinoline-benzenesulfonamide derivatives exert potent anti-lymphoma effect by targeting NF-κB.
Matko Kalac, Michael Mangone, Alison Rinderspacher, Shi-Xian Deng, Luigi Scotto

iScience· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reversal of CYLD phosphorylation as a novel therapeutic approach for adult T-cell leukemia/lymphoma (ATLL).
Xin Xu, Matko Kalac, Michael Markson, Mark Chan, Joshua D Brody

Cell Death Dis· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma.
Matko Kalac, Jennifer K Lue, Emily Lichtenstein, Ithamar Turenne, Celeste Rojas

Br J Haematol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
Owen A O'Connor, Jennifer K Lue, Ahmed Sawas, Jennifer E Amengual, Changchun Deng, Matko Kalac

Lancet Oncol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.
Jennifer E Amengual, Renee Lichtenstein, Jennifer Lue, Ahmed Sawas, Changchun Deng, Matko Kalac

Blood· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Update on the Use of Immunotherapy in the Treatment of Lymphoma.
Thomas U Marron, Matko Kalac, Joshua Brody

Curr Hematol Malig Rep· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma.
Enrica Marchi, Kelly M Zullo, Jennifer E Amengual, Matko Kalac, Danielle Bongero

Br J Haematol· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Propolis and its Active Component, Caffeic Acid Phenethyl Ester (CAPE), Modulate Breast Cancer Therapeutic Targets via an Epigenetically Mediated Mechanism of Action.
Coral Omene, Matko Kalac, Jing Wu, Enrica Marchi, Krystyna Frenkel

J Cancer Sci Ther· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma.
Jennifer E Amengual, Sean Clark-Garvey, Matko Kalac, Luigi Scotto, Enrica Marchi

Blood· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and characterization of a novel CD19CherryLuciferase (CD19CL) transgenic mouse for the preclinical study of B-cell lymphomas.
Luigi Scotto, Marianna Kruithof-de Julio, Luca Paoluzzi, Matko Kalac, Enrica Marchi

Clin Cancer Res· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL.
Matko Kalac, Luigi Scotto, Enrica Marchi, Jennifer Amengual, Venkatraman E Seshan

Blood· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Autologous stem cell transplantation in patients with relapsed or refractory Hodgkin's disease].
Hrvoje Minigo, Radovan Vrhovac, Matko Kalac, Branimir Jaksić

Acta Med Croatica· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New drugs for the treatment of lymphoma.
Luca Paoluzzi, Yukiko Kitagawa, Matko Kalac, Jasmine Zain, Owen A O'Connor

Hematol Oncol Clin North Am· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia.
Matko Kalac, Alfonso Quintás-Cardama, Radovan Vrhovac, Hagop Kantarjian, Srdan Verstovsek

Cancer· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[The disappearance of CD20 positive lymphocytes in the pleural effusion after intrapleural application of rituximab].
Matko Kalac, Slobodanka Ostojić Kolonić, Ika Kardum-Skelin, Ana Planinc-Peraica, Zoran Siftar

Acta Med Croatica· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Microcellular lung carcinoma in patient with hepatosplenic T-cell lymphoma: a case report].
Matko Kalac, Slobodanka Ostojić, Slavko Gasparov, Ana Planinc-Peraica, Mara Dominis

Lijec Vjesn· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis